1
|
Schnelzer A, Harter P, Sehouli J, Canzler U, Marmé F, De Gregorio N, Buderath P, Lück HJ, Gropp-Meier M, Runnebaum I, Belau A, Renner S, Schmalfeldt B, El-Balat A, Burges A, Hillemanns P, Denschlag D, Bauerschlag D, Hanker L, Ray-Coquard I. Phase III PAOLA-1/ENGOT-ov25 trial: Olaparib plus bevacizumab (bev) as maintenance therapy in patients (pts) with newly diagnosed, advanced ovarian cancer (OC) treated with platinum-based chemotherapy (PCh) plus bev. Geburtshilfe Frauenheilkd 2020. [DOI: 10.1055/s-0040-1717197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022] Open
Affiliation(s)
- A Schnelzer
- Universitätsfrauenklinik TU München Klinikum rechts der Isar
- RoMed Klinikum Rosenheim, Gynäkologie und Geburtshilfe
| | | | | | - U Canzler
- Universitätsfrauenklinik, Technische Universität Dresden
| | - F Marmé
- Universitätsfrauenklinik Heidelberg
- Universitätsfrauenklinik Mannheim
| | | | | | | | | | | | - A Belau
- Universitätsfrauenklinik Greifswald
- Gynäkologische Praxis
| | - S Renner
- Universitätsfrauenklinik Erlangen
| | | | | | - A Burges
- Universitätsfrauenklinik München Großhadern
| | | | | | | | | | | |
Collapse
|
2
|
de Gregorio N, Park-Simon TW, Meier W, Kommoss S, Hilpert F, Lück HJ, Baumann K, Harter P, Sehouli J, Canzler U, Schmalfeldt B, Hein A, Hanker L, Marmé F, El-Balat A, Mahner S, Kimmig R, Burges A, Schröder W, Jackisch C, Gropp-Meier M, Fehm T, Hasenburg A, Denschlag D, Belau A, Pfisterer J. Carboplatin/Caelyx/Bevacizumab vs. Carboplatin/Gemcitabine/Bevacizumab beim platinsensiblen Ovarialkarzinomrezidiv: Ergebnisse der prospektiv-randomisierten Phase III AGO-OVAR 2.21 Studie. Geburtshilfe Frauenheilkd 2019. [DOI: 10.1055/s-0039-1693899] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
Affiliation(s)
| | | | - W Meier
- Evangelisches Krankenhaus Düsseldorf
| | | | - F Hilpert
- Universitätsklinikum Schleswig-Holstein, Campus Kiel
| | - HJ Lück
- Gynäkologisch-Onkologische Praxis Hannover
| | | | | | | | - U Canzler
- Universitätsklinikum an der TU Dresden
| | | | - A Hein
- Universitäts-Frauenklinik Erlangen
| | | | - F Marmé
- Universitätsklinikum Heidelberg
| | | | | | | | | | | | | | | | - T Fehm
- Universitätsklinikum Düsseldorf
| | - A Hasenburg
- Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz
| | | | - A Belau
- Universitätsmedizin Greifswald
| | | |
Collapse
|
3
|
Heitz F, Kommoss S, Baumann K, Hilpert F, Brucker SY, Schröder W, Burges A, Canzler U, Belau A, Hanker L, Sehouli J, du Bois A, Pfisterer J. Vorhersage des Tumorrestes beim fortgeschrittenen Ovarialkarzinom durch Nutzung einer Gesamt-Transkription-Expressionsanalyse. Eine Analyse der AGO-OVAR 11 (ICON7) Studie. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671036] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- F Heitz
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Department for Gynecology and Gynecologic Oncology, Essen, Deutschland
| | - S Kommoss
- Universitäts-Frauenklinik Tübingen, Department for Gynecology and Gynecologic Oncology, Tübingen, Deutschland
| | - K Baumann
- Klinikum der Stadt Ludwigshafen, Frauenklinik, Ludwigshafen, Deutschland
| | - F Hilpert
- Onkologisches Therapiezentrum Hamburg am Krankenhaus Jerusalem, Hamburg, Deutschland
| | - SY Brucker
- Universitäts-Frauenklinik Tübingen, Department für Frauengesundheit, Tübingen, Deutschland
| | - W Schröder
- Gynaekologicum Bremen, Bremen, Deutschland
| | - A Burges
- Klinikum der Universität München – LMU, Campus Großhadern, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - U Canzler
- Universitätsklinikum Carl Gustav Carus Dresden, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Dresden, Deutschland
| | - A Belau
- Universitätsmedizin Greifswald, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Greifswald, Deutschland
| | - L Hanker
- Universitätsklinikum Schleswig-Holstein; Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Deutschland
| | - J Sehouli
- Charité, Campus Virchow-Klinikum, Universitätsmedizin Berlin, Klinik für Frauenheilkunde, Berlin, Deutschland
| | - A du Bois
- Kliniken Essen-Mitte, Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - J Pfisterer
- Zentrum für Gynäkologische Onkologie Kiel, Kiel, Deutschland
| |
Collapse
|
4
|
Kommoss S, Heitz F, Winterhoff B, Wang C, Canzler U, Aliferis C, Belau A, Wang J, Hanker L, Kommoss F, du Bois A, Ma S, Sehouli J, Kimmig R, Tourani R, Kurzeder C, Mahner S, Park-Simon TW, Dowdy SC, Pfisterer J. Significant overall survival improvement in proliferative subtype ovarian cancer patients receiving bevacizumab. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671332] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- S Kommoss
- Department für Frauengesundheit, Universitätsklinikum Tübingen, Tübingen, Deutschland
| | - F Heitz
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - B Winterhoff
- University of Minnesota, Division of Gynecologic Oncology, Minneapolis, Vereinigte Staaten von Amerika
| | - C Wang
- Mayo Clinic, Rochester, Vereinigte Staaten von Amerika
| | - U Canzler
- Uni.-Klinikum Carl Gustav Carus, Dresden, Deutschland
| | - C Aliferis
- Academic Health Center, University of Minnesota, Institute for Health Informatics (IHI), Minneapolis, Vereinigte Staaten von Amerika
| | - A Belau
- Universitätsmedizin Greifswald, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, Greifswald, Deutschland
| | - J Wang
- Academic Health Center, University of Minnesota, Institute for Health Informatics (IHI), Minneapolis, Vereinigte Staaten von Amerika
| | - L Hanker
- Universitätsklinikum Schleswig-Holstein Campus Lübeck, Klinik für Frauenheilkunde und Geburtshilfe, Lübeck, Deutschland
| | - F Kommoss
- Institut für Pathologie im Medizin Campus Bodensee Friedrichshafen, Friedrichshafen, Deutschland
| | - A du Bois
- Kliniken Essen-Mitte (KEM), Gynäkologie und Gynäkologische Onkologie, Essen, Deutschland
| | - S Ma
- Academic Health Center, University of Minnesota, Institute for Health Informatics (IHI), Minneapolis, Vereinigte Staaten von Amerika
| | - J Sehouli
- Universitätsmedizin Berlin Charité, Campus Virchow Klinikum, Klinik für Frauenheilkunde, Berlin, Deutschland
| | - R Kimmig
- Universitätsklinikum Essen, Frauenklinik, Essen, Deutschland
| | - R Tourani
- Academic Health Center, University of Minnesota, Institute for Health Informatics (IHI), Minneapolis, Vereinigte Staaten von Amerika
| | - C Kurzeder
- Universitätsspital Basel, Frauenklinik, Basel, Schweiz
| | - S Mahner
- Klinikum der Ludwig-Maximilians-Universität München, Klinik und Poliklinik für Frauenheilkunde und Geburtshilfe, München, Deutschland
| | - TW Park-Simon
- Medizinische Hochschule Hannover, Gynäkologische Onkologie, Hannover, Deutschland
| | - SC Dowdy
- Mayo Clinic, Rochester, Vereinigte Staaten von Amerika
| | - J Pfisterer
- Zentrum für Gynäkologische Onkologie Kiel, Kiel, Deutschland
| |
Collapse
|
5
|
Hasenburg A, Sehouli J, Lampe B, Reuss A, Schmalfeldt B, Belau A, Bossart M, Mahner S, Hillemanns P, Petry KU, du Bois A, Herwig U, Hilpert F, Gropp-Meier M, Hanf V, Janni W, Schindelhauer A, Kimmig R, Greimel E, Wagner U, Harter P. LION-PAW – Lymphonodectomy (LNE) in Ovarian Neoplasm – Pleasure Ability of Women Prospektive Substudie der multizentrischen AGO LION Studie. Geburtshilfe Frauenheilkd 2018. [DOI: 10.1055/s-0038-1671032] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022] Open
Affiliation(s)
- A Hasenburg
- Universitätsmedizin Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Mainz, Deutschland
| | - J Sehouli
- Charité, Campus Virchow Klinikum, Berlin, Deutschland
| | - B Lampe
- Kaiserswerther Diakonie/Florence Nightingale Krankenhaus, Düsseldorf, Deutschland
| | - A Reuss
- Philipps-University of Marburg, Coordinating Center for Clinical Trials, Marburg, Deutschland
| | - B Schmalfeldt
- Klinikum rechts der Isar; Technical University of Munich, München, Deutschland
- University Medical Center Hamburg-Eppendorf, Dept. of Gynecology and Gynecologic Oncology, Hamburg, Deutschland
| | - A Belau
- University of Greifswald, Clinic and Policlinic for Gynecology and Obstetrics, Greifswald, Deutschland
| | - M Bossart
- Universitätsklinik Freiburg, Universitätsfrauenklinik, Freiburg, Deutschland
| | - S Mahner
- University Medical Center Hamburg-Eppendorf, Dept. of Gynecology and Gynecologic Oncology, Hamburg, Deutschland
- Universitätsfrauenklinik LMU München, Geburtshilfe und Frauenheilkunde, München, Deutschland
| | - P Hillemanns
- Medizinische Hochschule Hannover, Klinik für Frauenheilkunde und Geburtshilfe, Hannover, Deutschland
| | - KU Petry
- Klinikum Wolfsburg, Frauenklinik, Wolfsburg, Deutschland
| | - A du Bois
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gyn. Onkologie, Essen, Deutschland
| | - U Herwig
- Albertinen-Hospital Hamburg, Research Center Gynecology, Hamburg, Deutschland
| | - F Hilpert
- Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Deutschland
| | - M Gropp-Meier
- Oberschwabenklinik, Krankenhaus St. Elisabeth, Ravensburg, Deutschland
| | - V Hanf
- Klinikum Fürth, Frauenklinik, Fürth, Deutschland
| | - W Janni
- University of Ulm, Department of Gynecology, Ulm, Deutschland
| | - A Schindelhauer
- Medical Faculty and University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Deutschland
| | - R Kimmig
- Universitätsklinikum Essen, Frauenklinik, Essen, Deutschland
| | - E Greimel
- Medical University Graz, Department of Obstetrics and Gynecology, Graz, Österreich
| | - U Wagner
- University of Gießen and Marburg GmbH Site Marburg, Klinik für Gynäkologie, Gyn. Endokrinologie und Onkologie, Marburg, Deutschland
| | - P Harter
- Kliniken Essen-Mitte (KEM) Evang. Huyssens-Stiftung/Knappschaft GmbH, Klinik für Gynäkologie und gyn. Onkologie, Essen, Deutschland
| |
Collapse
|
6
|
von Minckwitz G, Loibl S, Untch M, Eidtmann H, Rezai M, Fasching PA, Tesch H, Eggemann H, Schrader I, Kittel K, Hanusch C, Huober J, Solbach C, Jackisch C, Kunz G, Blohmer JU, Hauschild M, Fehm T, Nekljudova V, Gerber B, Gnauert K, Heinrich B, Prätz T, Groh U, Tanzer H, Villena C, Tulusan A, Liedtke B, Blohmer JU, Kittel K, Mau C, Potenberg J, Schilling J, Just M, Weiss E, Bückner U, Wolfgarten M, Lorenz R, Doering G, Feidicker S, Krabisch P, Deichert U, Augustin D, Kunz G, Kast K, von Minckwitz G, Nestle-Krämling C, Rezai M, Höß C, Terhaag J, Fasching P, Staib P, Aktas B, Kühn T, Khandan F, Möbus V, Solbach C, Tesch H, Stickeler E, Heinrich G, Wagner H, Abdallah A, Dewitz T, Emons G, Belau A, Rethwisch V, Lantzsch T, Thomssen C, Mattner U, Nugent A, Müller V, Noesselt T, Holms F, Müller T, Deuker JU, Schrader I, Strumberg D, Uleer C, Solomayer E, Runnebaum I, Link H, Tomé O, Ulmer HU, Conrad B, Feisel-Schwickardi G, Eidtmann H, Schumacher C, Steinmetz T, Bauerfeind I, Kremers S, Langanke D, Kullmer U, Ober A, Fischer D, Kohls A, Weikel W, Bischoff J, Freese K, Schmidt M, Wiest W, Sütterlin M, Dietrich M, Grießhammer M, Burgmann DM, Hanusch C, Rack B, Salat C, Sattler D, Tio J, von Abel E, Christensen B, Burkamp U, Köhne CH, Meinerz W, Graßhoff ST, Decker T, Overkamp F, Thalmann I, Sallmann A, Beck T, Reimer T, Bartzke G, Deryal M, Weigel M, Huober J, Weder P, Steffens CC, Lemster S, Stefek A, Ruhland F, Hofmann M, Schuster J, Simon W, Kronawitter U, Clemens M, Fehm T, Janni W, Latos K, Bauer W, Roßmann A, Bauer L, Lampe D, Heyl V, Hoffmann G, Lorenz-Salehi F, Hackmann J, Schlag R. Survival after neoadjuvant chemotherapy with or without bevacizumab or everolimus for HER2-negative primary breast cancer (GBG 44-GeparQuinto)†. Ann Oncol 2014; 25:2363-2372. [PMID: 25223482 DOI: 10.1093/annonc/mdu455] [Citation(s) in RCA: 97] [Impact Index Per Article: 9.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
BACKGROUND The GeparQuinto study showed that adding bevacizumab to 24 weeks of anthracycline-taxane-based neoadjuvant chemotherapy increases pathological complete response (pCR) rates overall and specifically in patients with triple-negative breast cancer (TNBC). No difference in pCR rate was observed for adding everolimus to paclitaxel in nonearly responding patients. Here, we present disease-free (DFS) and overall survival (OS) analyses. PATIENTS AND METHODS Patients (n = 1948) with HER2-negative tumors of a median tumor size of 4 cm were randomly assigned to neoadjuvant treatment with epirubicin/cyclophosphamide followed by docetaxel (EC-T) with or without eight infusions of bevacizumab every 3 weeks before surgery. Patients without clinical response to EC ± Bevacizumab were randomized to 12 weekly cycles paclitaxel with or without everolimus 5 mg/day. To detect a hazard ratio (HR) of 0.75 (α = 0.05, β = 0.8) 379 events had to be observed in the bevacizumab arms. RESULTS With a median follow-up of 3.8 years, 3-year DFS was 80.8% and 3-year OS was 89.7%. Outcome was not different for patients receiving bevacizumab (HR 1.03; P = 0.784 for DFS and HR 0.974; P = 0.842 for OS) compared with patients receiving chemotherapy alone. Patients with TNBC similarly showed no improvement in DFS (HR = 0.99; P = 0.941) and OS (HR = 1.02; P = 0.891) when treated with bevacizumab. No other predefined subgroup (HR+/HER2-; locally advanced (cT4 or cN3) or not; cT1-3 or cT4; pCR or not) showed a significant benefit. No difference in DFS (HR 0.997; P = 0.987) and OS (HR 1.11; P = 0.658) was observed for nonearly responding patients receiving paclitaxel with or without everolimus overall as well as in subgroups. CONCLUSIONS Long-term results, in opposite to the results of pCR, do not support the neoadjuvant use of bevacizumab in addition to an anthracycline-taxane-based chemotherapy or everolimus in addition to paclitaxel for nonearly responding patients. CLINICAL TRIAL NUMBER NCT 00567554, www.clinicaltrials.gov.
Collapse
Affiliation(s)
- G von Minckwitz
- Headquarter, German Breast Group, Neu-Isenburg; Department of Gynaecology and Obstetrics, University Hospital, Frankfurt.
| | - S Loibl
- Headquarter, German Breast Group, Neu-Isenburg
| | - M Untch
- Department of Gynaecology and Obstetrics, Klinikum Berlin-Buch, Berlin
| | - H Eidtmann
- Department of Gynaecology and Obstetrics, University Hospital, Kiel
| | - M Rezai
- Breast Center, Luisenkrankenhaus, Düsseldorf
| | - P A Fasching
- Department of Gynaecology and Obstetrics, University Hospital, Erlangen
| | - H Tesch
- Department of Medical Oncology, Chop GmbH, Frankfurt
| | - H Eggemann
- Department of Gynaecology and Obstetrics, University Hospital, Magdeburg
| | - I Schrader
- Department of Gynaecology and Obstetrics, Henriettenstiftung, Hannover
| | - K Kittel
- Department of Gynaecology and Obstetrics, Praxisklinik, Berlin
| | - C Hanusch
- Department of Gynaecology and Obstetrics, Rot-Kreuz-Klinikum, München
| | - J Huober
- Department of Gynaecology and Obstetrics, University Hospital, Ulm
| | - C Solbach
- Department of Gynaecology and Obstetrics, University Hospital, Frankfurt
| | - C Jackisch
- Department of Gynaecology and Obstetrics, Sana-Klinikum, Offenbach
| | - G Kunz
- Department of Gynaecology and Obstetrics, St Johannes Hospital, Dortmund
| | - J U Blohmer
- Department of Gynaecology and Obstetrics, St Gertrauden-Hospital, Berlin
| | - M Hauschild
- Department of Gynaecology and Obstetrics, Hospital, Rheinfelden
| | - T Fehm
- Department of Gynaecology and Obstetrics, University Hospital, Tübingen
| | | | - B Gerber
- Department of Gynaecology and Obstetrics, University Hospital, Rostock, Germany
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
7
|
Mahner S, Hilpert F, Meier W, Sailer O, Hanker L, Canzler U, Sehouli J, Baumann K, Burges A, Gropp M, Hasenburg A, Belau A, Fehm T, Kosse J, Schmalfeldt B, Marme F, Cibula D, Richter B, Herwig U, Liebrich C, Gerber B, Potenberg J, Krabisch P, Thill M, Harter P, Kimmig R, de Gregorio N, Pfisterer J, Merger M, du Bois A. Unabhängige Analyse der AGO-OVAR 12, einer GCIG/ENGOT-Intergroup Phase III Studie mit Nintedanib in der Firstline Therapie beim Ovarialkarzinom. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388364] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
8
|
Kurzeder C, Schmalfeldt B, Grischke EM, Rau J, Meier W, Lück HJ, Hasenburg A, Belau A, Mahner S, Marmé F, Hilpert F, Gropp-Meier M, Zorr A, Vergote I, Hils R, Canzler U, Rein D, de Gregorio N, Jackisch C, Gerber B, du Bois A. Die AGO-OVAR 2.20/PENELOPE Studie – Therapie des platinresistenten Ovarialkarzinoms mit Pertuzumab (P) und Chemotherapie (CT) nach Biomarker-unterstützter Präselektion von Patienten. Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388353] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
9
|
Canzler U, Hilpert F, Meier W, Reuß A, Hanker LC, Sehouli J, Baumann K, Burges A, Gropp-Meier M, Hasenburg A, Belau A, Fehm T, Kosse J, Mahner S, Schmalfeldt B, Marmé F, Richter B, Cibula D, Harter P, Kimmig R, de Gregorio N, Pfisterer J, Merger M, du Bois A. AGO-OVAR 12: Eine randomisierte, Placebo-kontrollierte Phase III-Studie zum Einsatz von Carboplatin und Paclitaxel ± Nintedanib beim fortgeschrittenen Ovarialkarzinom (GCIG/ENGOT-Intergroup-Studie). Geburtshilfe Frauenheilkd 2014. [DOI: 10.1055/s-0034-1388329] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/24/2022] Open
|
10
|
Sinn BV, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Tesch H, Kronenwett R, Hoffmann G, Belau A, Thommsen C, Holzhausen HJ, Grasshoff ST, Baumann K, Mehta K, Dietel M, Loibl S. Evaluation of Mucin-1 protein and mRNA expression as prognostic and predictive markers after neoadjuvant chemotherapy for breast cancer. Ann Oncol 2013; 24:2316-24. [PMID: 23661292 DOI: 10.1093/annonc/mdt162] [Citation(s) in RCA: 27] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/03/2023] Open
Abstract
BACKGROUND Mucin-1 (MUC1) is a promising antigen for the development of tumor vaccines. We evaluated the frequency of MUC1 expression and its impact on therapy response and survival after neoadjuvant chemotherapy for breast cancer. PATIENTS AND METHODS Pre-treatment core biopsies of patients from the GeparTrio neoadjuvant trial (NCT 00544765) were evaluated for MUC1 by immunohistochemistry (IHC; N = 691) and quantitative RT-PCR (qRT-PCR; N = 286) from formalin-fixed paraffin-embedded (FFPE) samples. RESULTS MUC1 protein and mRNA was detectable in the majority of cases and was associated with hormone-receptor-positive status (P < 0.001). High MUC1 protein and mRNA expression were associated with lower probability of pathologic complete response (P = 0.017 and P < 0.001) and with longer patient survival (P = 0.03 and P < 0.001). In multivariable analysis, MUC1 protein and mRNA expression were independently predictive (P = 0.001 and P < 0.001). MUC1 protein and mRNA expression were independently prognostic for overall survival (P = 0.029 and P = 0.015). CONCLUSIONS MUC1 is frequently expressed in breast cancer and detectable on mRNA and protein level from FFPE tissue. It provides independent predictive information for therapy response and survival after neoadjuvant chemotherapy. In clinical immunotherapy trials, MUC1 expression may serve as a predictive marker.
Collapse
Affiliation(s)
- B V Sinn
- Department of Pathology, Charité-Universitätsmedizin Berlin, Berlin.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Lee CK, Simes RJ, Brown C, Gebski V, Pfisterer J, Swart AM, Berton-Rigaud D, Plante M, Skeie-Jensen T, Vergote I, Schauer C, Pisano C, Parma G, Baumann K, Ledermann JA, Pujade-Lauraine E, Bentley J, Kristensen G, Belau A, Nankivell M, Canzler U, Lord SJ, Kurzeder C, Friedlander M. A prognostic nomogram to predict overall survival in patients with platinum-sensitive recurrent ovarian cancer. Ann Oncol 2012; 24:937-43. [PMID: 23104722 DOI: 10.1093/annonc/mds538] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND Patients with platinum-sensitive recurrent ovarian cancer have variable prognosis and survival. We extend previous work on prediction of progression-free survival by developing a nomogram to predict overall survival (OS) in these patients treated with platinum-based chemotherapy. PATIENTS AND METHODS The nomogram was developed using data from the CAELYX in Platinum-Sensitive Ovarian Patients (CALYPSO) trial. Multivariate proportional hazards models were generated based on pre-treatment characteristics to develop a nomogram that classifies patient prognosis based on OS outcome. We also developed two simpler models with fewer variables and conducted model validations in independent datasets from AGO-OVAR Study 2.5 and ICON 4. We compare the performance of the nomogram with the simpler models by examining the differences in the C-statistics and net reclassification index (NRI). RESULTS The nomogram included six significant predictors: interval from last platinum chemotherapy, performance status, size of the largest tumour, CA-125, haemoglobin and the number of organ sites of metastasis (C-statistic 0.67; 95% confidence interval 0.65-0.69). Among the CALPYSO patients, the median OS for good, intermediate and poor prognosis groups was 56.2, 31.0 and 20.8 months, respectively. When CA-125 was not included in the model, the C-statistics were 0.65 (CALYPSO) and 0.64 (AGO-OVAR 2.5). A simpler model (interval from last platinum chemotherapy, performance status and CA-125) produced a significant decrease of the C-statistic (0.63) and NRI (26.4%, P < 0.0001). CONCLUSIONS This nomogram with six pre-treatment characteristics improves OS prediction in patients with platinum-sensitive ovarian cancer and is superior to models with fewer prognostic factors or platinum chemotherapy free interval alone. With independent validation, this nomogram could potentially be useful for improved stratification of patients in clinical trials and also for counselling patients.
Collapse
Affiliation(s)
- C K Lee
- NHMRC Clinical Trials Centre, University of Sydney, Sydney, Australia.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Sehouli J, Runnebaum IB, Fotopoulou C, Blohmer U, Belau A, Leber H, Hanker LC, Hartmann W, Richter R, Keyver-Paik MD, Oberhoff C, Heinrich G, du Bois A, Olbrich C, Simon E, Friese K, Kimmig R, Boehmer D, Lichtenegger W, Kuemmel S. A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup Study. Ann Oncol 2012; 23:2259-2264. [PMID: 22357252 DOI: 10.1093/annonc/mdr628] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/27/2023] Open
Abstract
BACKGROUND Simultaneous adjuvant platinum-based radiochemotherapy in high-risk cervical cancer (CC) is an established treatment strategy. Sequential paclitaxel (Taxol) and platinum followed by radiotherapy may offer further advantages regarding toxicity. PATIENTS AND METHODS An open-labeled randomized phase III trial was conducted to compare paclitaxel (175 mg/m(2)) plus carboplatin (AUC5) followed by radiation (50.4 Gy) (experimental arm-A) versus simultaneous radiochemotherapy with cisplatin (40 mg/m(2)/week) (arm-B) in patients with stage IB-IIB CC after surgery. Primary objective was progression-free survival (PFS). RESULTS Overall, 271 patients were randomized and 263 were eligible for evaluation; 132 in arm-A and 131 in arm-B appropriately balanced. The estimated 2-year PFS was 81.8% [95% confidence interval (CI) 74.4-89.1] in arm-B versus 87.2% (95% CI 81.2-93.3) in arm-A (P = 0.235) and the corresponding 5-year survival rates were 85.8% in arm-A and 78.9% in arm-B (P = 0.25). Hematological grade 3/4 toxicity was higher in arm-B. Alopecia (87.9% versus 4.1%; P < 0.001) and neurotoxicity (65.9% versus 15.6%; P < 0.001) were significantly higher in arm-A. Early treatment termination was significantly more frequent in arm-B than in arm-A (32.1% versus 12.9%; P = 0.001). CONCLUSIONS Sequential chemotherapy and radiation in high-risk CC could not show any significant survival benefit; however, a different toxicity profile appeared. This sequential regime may constitute an alternative option when contraindications for immediate postoperative radiation are present.
Collapse
Affiliation(s)
- J Sehouli
- Department of Gynecology, European Competence Centre for Ovarian Cancer, Charité-University Hospital, Berlin.
| | - I B Runnebaum
- Department of Gynecology, Jena University Hospital, Jena
| | - C Fotopoulou
- Department of Gynecology, European Competence Centre for Ovarian Cancer, Charité-University Hospital, Berlin
| | - U Blohmer
- Brustzentrum, Sankt-Gertrauden-Krankenhaus, Berlin
| | - A Belau
- Department of Gynecology, Ernst-Moritz-Arndt-Universität Greifswald, Greifswald
| | - H Leber
- Klinik fuer Strahlentherapie, Bruederkrankenhaus St Josef, Paderborn
| | - L C Hanker
- Department of Obstetrics and Gynecology, J.W. Goethe-University, Frankfurt
| | - W Hartmann
- Department of Gynecology, Klinikum Frankfurt (Oder) GmbH, Frankfurt-Oder
| | - R Richter
- Department of Gynecology, European Competence Centre for Ovarian Cancer, Charité-University Hospital, Berlin
| | | | - C Oberhoff
- Department of Gynecology, Kath. Kliniken Essen-Nord Marienhospital, Altenessen
| | | | - A du Bois
- Department of Gynecology, Horst Schmidt Klinik, Wiesbaden
| | - C Olbrich
- Department of Gynecology, DRK Kliniken Berlin Westend, Berlin
| | - E Simon
- Department of Gynecology, Kreiskrankenhaus Torgau Johann Kentmann GmbH, Torgau
| | - K Friese
- Department of Gynecology, Universitätsklinik LMU, Munich
| | - R Kimmig
- Department of Gynecology, Universitätsklinikum Essen, Essen
| | - D Boehmer
- Department of Radiation Oncology, Charite-University Medicine Berlin, Campus Virchow-Klinikum, Berlin
| | - W Lichtenegger
- Department of Gynecology, European Competence Centre for Ovarian Cancer, Charité-University Hospital, Berlin
| | - S Kuemmel
- Brustzentrum, Kliniken Essen-Mitte, Essen, Germany
| |
Collapse
|
13
|
Sinn B, von Minckwitz G, Denkert C, Eidtmann H, Darb-Esfahani S, Belau A, Kronenwett R, Holzhausen H, Mehta K, Loibl S. 8O_PR MUCIN-1 Protein and Mrna Expression in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy. Ann Oncol 2012. [DOI: 10.1093/annonc/mds039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
14
|
Mustea A, Belau A, Sehouli J, Drzewiecki K, Eichbaum MHR, Bartz K, Angelidou E, Saegner S, Langenbruch MO, Ledwon P, Zygmunt M, Koehler G, Koensgen D. Response rate and toxicity of primary concomitant radio-chemotherapy in locally advanced cervical cancer: Results of an open prospective, multicenter phase II study of the NOGGO. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5038] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
15
|
Koensgen D, Belau A, Sehouli J, Sommer HL, Bartz K, Markmann S, Schneidewind L, Scharf JP, Ehmke M, Stengel D, Ledwon P, Guba H, Zygmunt M, Koehler G, Mustea A. Adjuvant sequential chemo-radiation therapy in high-risk endometrial cancer: Results of a prospective, multicenter phase II study of the NOGGO. J Clin Oncol 2011. [DOI: 10.1200/jco.2011.29.15_suppl.5109] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
16
|
Sehouli J, Blohmer JU, Kuemmel S, Runnebaum IB, Hartmann W, Richter R, Belau A, Leber H, Kaufmann M, Lichtenegger W. Randomized phase III adjuvant study in high-risk cervical cancer: Simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): A NOGGO-AGO-Intergroup Study. J Clin Oncol 2010. [DOI: 10.1200/jco.2010.28.15_suppl.5005] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|
17
|
Sehouli J, Oskay-Özcelik G, Stengel D, Harter P, Kurzeder C, Belau A, Markmann S, Lorenz R, Mueller L, Lichtenegger W. 8002 What is the best schedule of Topotecan? – weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer – a randomized, multicenter trial of the North-Eastern German Society of Gynaecological Oncology (TOWER). EJC Suppl 2009. [DOI: 10.1016/s1359-6349(09)71524-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
18
|
Sehouli J, Oskay-Oezcelik G, Stengel D, Harter P, Kurzeder C, Belau A, Belau A, Markmann S, Lorenz R, Mueller L, Lichtenegger W. Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, multicenter trial of the North-Eastern German Society of Gynecological Oncology (NOGGO). J Clin Oncol 2009. [DOI: 10.1200/jco.2009.27.15_suppl.5553] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5553 Background: In women with platinum-resistant recurrent ovarian cancer, weekly administration of topotecan (Tw) may be equally effective, but better tolerated than conventional 5-day dosing (Tc). We conducted a randomized multicenter trial to validate this assumption. Methods: The trial was pre-registered at clinicaltrials.gov ( NCT00170677 ). Women with platinum-resistant ovarian and fallopian tube cancers or primary peritoneal carcinoma, and measurable or assessable disease (GCIG criteria) were randomized to receive either Tw (d1,8,15/q28d, 4 mg/m2) or Tc (d1–5/q21d, 1.25 mg/m2). The predefined stopping rule, based on the primary endpoint of best CA-125 or tumor response, was not reached (presented at ASCO 2007, Abstract 5526). This permitted the accrual of 194 patients, 154 of whom could be assessed for CA-125 or tumor response (SD + CR + PR). We also compared progression-free (PFS) and overall survival (OS), as well as toxicity between trial groups. Results: Mean age was 61.8 (SD 9.8) years, and 59 women were on third-line treatment. Patients received a total of 809 cycles of chemotherapy. Demographic baseline characteristics, tumor stages and grades, and previous lines of chemotherapy were well balanced between treatment groups. There were 35 / 75 (47%) and 45 / 79 (57%) responses in the Tw and Tc groups, respectively (risk ratio [RR] 1.22, 95% CI 0.89–1.66). Median PFS and OS did not differ markedly between both regimens (3.2 versus 4.4 months, hazard ratio [HR] 1.30, 95% CI 0.96–1.77 and 9.8 versus 10.0 months, HR 1.08, 95% CI 0.77–1.52). The risk of grade III/IV hematological toxicity was significantly lower in the Tw group (anemia: RR 0.35, p = 0.007, neutropenia: RR 0.38, p = 0.0001, thrombopenia: RR 0.23, p = 0.0004). Conclusions: Weekly administration of topotecan shows no substantial difference in endpoints of effectiveness compared to conventional dosing, but is associated with a significantly lower likelihood of severe hematological toxicity. Weekly topotecan should be considered as a possible treatment alternative in women with platinum-resistant ovarian cancer because of its favourable benefit-risk-profile. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Sehouli
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - G. Oskay-Oezcelik
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - D. Stengel
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - P. Harter
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - C. Kurzeder
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - A. Belau
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - A. Belau
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - S. Markmann
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - R. Lorenz
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - L. Mueller
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| | - W. Lichtenegger
- University Hospital Charite, Berlin, Germany; Unfallkrankenhaus Berlin, Berlin, Germany; Horst Schmidt Klinikum, Wiesbaden, Germany; University Hospital, Ulm, Germany; University Hospital, Greifswald, Germany; University Hoospital, Rostock, Germany; Praxis, Braunschweig, Germany; Onkologische Schwerpunktpraxis Leer und Emden, Leer und Emden, Germany
| |
Collapse
|
19
|
Lück HJ, du Bois A, Sehouli J, Reinhartz S, Belau A, Pfisterer J. Immunologische Therapieansätze in der Behandlung des fortgeschrittenen Ovarialcarcinoms – AGO OVAR–2.8 und OVAR–10 (MIMOSA). Geburtshilfe Frauenheilkd 2008. [DOI: 10.1055/s-0028-1089307] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022] Open
|
20
|
Loibl S, Pfisterer J, Wimberger P, Kurzeder C, Du Bois A, Sehouli J, Belau A, Burchardi N, Vergote I, Wagner U. 5005 ORAL Randomized, multicenter, 2-dose-level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. EJC Suppl 2007. [DOI: 10.1016/s1359-6349(07)71177-1] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
21
|
Pfisterer J, du Bois A, Sehouli J, Loibl S, Reinartz S, Reuss A, Canzler U, Belau A, Jackisch C, Kimmig R, Wollschlaeger K, Heilmann V, Hilpert F. The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. Ann Oncol 2007; 17:1568-77. [PMID: 17005631 DOI: 10.1093/annonc/mdl357] [Citation(s) in RCA: 55] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
BACKGROUND Abagovomab is a murine anti-idiotypic antibody against the antigen CA-125 which has been shown to elicit humoral and cellular immune responses against ovarian cancer (oc). PATIENTS AND METHODS This phase I trial included 36 patients with recurrent oc comparing two subcutaneous (s.c.) vaccination schedules: nine (group L) versus six injections (group S), 18 patients in each group. Four injections of 2.0 mg abagovomab were administered every 2 weeks and then two or five additional doses monthly. Primary endpoint was drop-out rate due to toxicity, and the secondary endpoint was analysis of immunological response. RESULTS Treatment was completed in eight (44%) and 16 (89%) patients in groups L and S, respectively. Premature termination occurred due to patient withdrawal or disease progression. No treatment-limiting toxicities occurred in either group. The most common toxicity related to the vaccine was grade 1/2 local injection site reaction. Induction of Ab3 was observed in all evaluable patients. There were no differences between the groups with regard to induction of human anti-mouse antibody (P = 0.1006). IFNgamma-expressing CA125-specific CD8+ T-cells were significantly more frequent in group L, while there was no significant difference between CD4+ T-cells in the two groups. CONCLUSIONS Abagovomab s.c. vaccination is safe and well tolerated. The long vaccination schedule tended to be more effective with regard to AB3-induction and cellular cytotoxicity.
Collapse
MESH Headings
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Anti-Idiotypic/adverse effects
- Antibodies, Anti-Idiotypic/blood
- Antibodies, Anti-Idiotypic/therapeutic use
- Antibodies, Monoclonal
- Antibodies, Monoclonal, Murine-Derived
- CA-125 Antigen/blood
- CA-125 Antigen/immunology
- Cancer Vaccines/therapeutic use
- Carcinoma, Papillary/immunology
- Carcinoma, Papillary/therapy
- Female
- Humans
- Immunity, Cellular
- Middle Aged
- Neoplasm Recurrence, Local/therapy
- Neoplasms, Glandular and Epithelial/immunology
- Neoplasms, Glandular and Epithelial/therapy
- Ovarian Neoplasms/immunology
- Ovarian Neoplasms/therapy
- Patient Compliance
- Peritoneal Neoplasms/secondary
- Peritoneal Neoplasms/therapy
- Vaccines, DNA/adverse effects
- Vaccines, DNA/therapeutic use
Collapse
Affiliation(s)
- J Pfisterer
- Klinik für Gynäkologie und Geburtshilfe, Campus Kiel, Universitätsklinikum Schleswig-Holstein, Kiel, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
22
|
Belau A, Pfisterer J, Wimberger P, Kurzeder C, Du Bois A, Sehouli J, Loibl S, Burchardi N, Vergote I, Wagner U. Randomized, multicenter, two-dose level, open-label, phase IIa study with the intraperitoneally infused trifunctional bispecific antibody catumaxomab (anti-EpCAM × anti-CD3) to select the better dose level in platinum refractory epithelial ovarian cancer patients. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5556] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5556 Background: The trifunctional antibody catumaxomab specifically binds EpCAM+ tumor cells, CD3+ T lymphocytes and accessory cells via the Fcγ RI/III thereby inducing a tumor specific cell mediated cytotoxicity in vitro and in vivo. This study was conducted to evaluate efficacy and safety of two different regimens of catumaxomab. Methods: Women with platinum-refractory (progressing during or ≤ 6 mos. after the last platinum containing regimen) epithelial ovarian cancer and measurable recurrent disease were randomized to receive either 10 -10 -10 - 10 μg or 10–20–50–100 μg of catumaxomab over 6h i.p on days 0, 3, 7 and 10. Results: 45 pts. were entered (22 high dose (HD)-arm, 23 low dose (LD)-arm). Both groups were well balanced concerning ECOG-perfomance score, with a median age of 65.6y in the HD- and 57.6y in the LD-arm and with a median diameter of measurable lesions of 90mm in the HD- and 104mm in the LD-arm. Based on the AEs, changes in laboratory parameters and other safety variables observed in the safety population in the course of this study, the accumulated safety experience is consistent with the key features of the mode of action of catumaxomab. Their intensity on median level was mostly mild to moderate. A clinical benefit was detectable in 27.3% of pts. for the HD- (1PR/5SD) and 8.7% of pts. for the LD-arm (2SD). After a median follow-up of 4.96 months, the median overall survival time was 182 d for the HD- and 114 d for the LD-arm. Conclusion: The results demonstrate that catumaxomab is safe with acceptable toxicity when administered as a sequence of 4 IP infusions at 10, 20, 50 and 100 μg. A modest dose effect is observed for the higher doses of catumaxomab. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- A. Belau
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| | - J. Pfisterer
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| | - P. Wimberger
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| | - C. Kurzeder
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| | - A. Du Bois
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| | - J. Sehouli
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| | - S. Loibl
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| | - N. Burchardi
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| | - I. Vergote
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| | - U. Wagner
- University, Greifswald, Germany; University, Mannheim, Germany; University, Marburg, Germany; University, Ulm, Germany; HSK, Wiesbaden, Germany; Charite, Berlin, Germany; University, Frankfurt, Germany; KKS, Marburg, Germany; University, Leuven, Belgium
| |
Collapse
|
23
|
Sehouli J, Oskay-Oezcelik G, Stengel D, du Bois A, Markmann S, Loibl S, Wilke J, Nugent A, Belau A, Lichtenegger W. Topotecan weekly versus routine 5-day schedule in patients with platinum-resistant ovarian cancer (TOWER): A randomized, two-stage phase-II study of the North-Eastern German Society of Gynaecological Oncology (NOGGO). J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.5526] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5526 Background: Optimizing the therapeutic index (that is, maintaining drug effectiveness while reducing toxicity) is a major goal in chemotherapy for platinum-resistant ovarian cancer. Early phase-I/II studies suggest that weekly topotecan (T) might be effective and apparently better tolerated than the established 5-day regimen. As yet, no randomized comparison of both regimes was attempted. To prove the hypothesis of an improved therapeutic index with weekly T, we conducted a randomized, multicenter, two-stage phase-II trial, and herein present the data of the planned interim analysis. Methods: Pts with platinresistent ovarian and fallopian tube cancers or primary peritoneal carcinoma, measurable or assessable disease (GCIG-CA-125 response criteria), were eligible. Pts were randomized to receive either weekly T (d1,8,15/q28d, 4 mg/m2) or T from d1–5/q21d at a dose of 1.25 mg/m2. According to Gehan’s two-stage-design, both arms were handled as independent studies. Overall response rate (CR + PR) was defined as primary study endpoint, secondary endpoints of the interim analysis were toxicity and safety. Results: 28 pts in the weekly and 21 pts in the conventional group, enrolled at 38 centers form the basis of this report. 230 cycles of chemotherapy were evaluated for toxicity analyses. Median age was 61 years (range, 36 - 82 years). Demographic baseline characteristics, including tumor stage and grade were well balanced between treatment arms. There were 2/28 and 5/21 responses in weekly and the conventional arm, respectively (Risk Ratio [RR] 0.30, 95% confidence interval [CI] 0.06 - 1.40, p=0.122). The risk of early treatment termination due to tumor progression (RR 1.39, 95%CI 0.75 - 2.56), haematological (RR 0.20, 95% CI 0.01 - 3.97) or non- hematological toxicities (RR 1.96, 95% CI 0.18 - 20.83) did not differ significantly between groups. The only three events of neutropenic fever occurred in the conventional arm (RR 1.70, 95% CI 0.99 - 1.16). Conclusions: Weekly T is well tolerated and potentially active. The second stage of this study will require additional 46 patients each arm. Complete enrolment is expected to be accomplished in May 2007. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- J. Sehouli
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| | - G. Oskay-Oezcelik
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| | - D. Stengel
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| | - A. du Bois
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| | - S. Markmann
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| | - S. Loibl
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| | - J. Wilke
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| | - A. Nugent
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| | - A. Belau
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| | - W. Lichtenegger
- University Hospital Charite, Berlin, Germany; Horst-Schmidt Hospital, Wiesbaden, Germany; University Hospital Rostock, Rostock, Germany; University Hospital Ulm, Ulm, Germany; Medical Hospital Fürth, Fürth, Germany; University Hospital Hamburg, Hamburg, Germany; University Hospital Greifswald, Greifswald, Germany
| |
Collapse
|
24
|
Koehler G, Sehouli J, Sommer H, Blohmer J, Bartz K, Belau A. Toxicity of adjuvant sequential chemo- and radiotherapy of high-risk endometrial carcinoma (HREC)—Results of a phase II multicenter feasibility NOGGO study. J Clin Oncol 2007. [DOI: 10.1200/jco.2007.25.18_suppl.16074] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
16074 Background: Isolated adjuvant radio- or chemotherapy (CHT) only reduces local or distant relapses in HREC without impact on overall-survival. Therefore a multicenter feasibility study on adjuvant sequential chemo- and radiotherapy of HREC was initiated in order to evaluate safety and toxicity. Planned number of patients was 40, if after 17 pts. no termination of therapy because of toxicity was necessary, study can be closed and a phase III-study can be initiated. The data on toxicity are presented. Methods: Eligibility criteria: adenocarcinomas G1/G2 stage IC or G3 stage IA-IC or all stages II and IIIA (histological), all tumours with more than 2 cm diameter in size or non endometrioid cancers stage IA-C, II and IIIA and all cases with vessel invasion. Surgery: abdominal hysterectomy with bilateral adnexectomy without lymphadenectomy or with pelvic and para-aortic lymphadenectomy and positive lymph nodes. Further: Karnofsky-Index > 70, normal bone marrow, kidney, and liver function with laboratory tests not higher than 1.5 times of the normal local reference values. CHT: 175 mg/m2 paclitaxel plus carboplatin AUC 5, q 3 weeks for 4 cycles beginning latest 6 weeks after surgery. Within 6 further weeks after CHT an external beam irradiation (total dose 50.4 Gy, 28 fractions with 1.8 GY/d) plus 3 intracavitary HDR-iridium-192- brachytherapy courses with 3 x 5 GY were performed. Results: To date 17 pts (mean 64.1 years) completed 68 cycles CHT and following radiotherapy. There was no termination of therapy. Grade III leucopenia was observed in 9 % with 2 pts. requiring prolongation of treatment interval. There were 3 and 1 % grade II anemia and thrombocytopenia respectively. Further grade II toxicity: alopecia 38, fatigue 12, nausea/emesis 3, sensory neuropathy 12 %. Administration of G-CSF (pegfilgrastim) and epoitin (darbepoetin) was necessary in 2 and 6 % of cycles. Conclusions: Adjuvant sequential chemo- and radiotherapy of HREC is feasible by safety and toxicity and a phase III study can be initiated. No significant financial relationships to disclose.
Collapse
Affiliation(s)
- G. Koehler
- Northeastern Society of Gynaecological Oncology, Germany; University, Greifswald, Germany; Charite, Berlin, Germany; University, Muenchen, Germany; Gertrauden, Berlin, Germany
| | - J. Sehouli
- Northeastern Society of Gynaecological Oncology, Germany; University, Greifswald, Germany; Charite, Berlin, Germany; University, Muenchen, Germany; Gertrauden, Berlin, Germany
| | - H. Sommer
- Northeastern Society of Gynaecological Oncology, Germany; University, Greifswald, Germany; Charite, Berlin, Germany; University, Muenchen, Germany; Gertrauden, Berlin, Germany
| | - J. Blohmer
- Northeastern Society of Gynaecological Oncology, Germany; University, Greifswald, Germany; Charite, Berlin, Germany; University, Muenchen, Germany; Gertrauden, Berlin, Germany
| | - K. Bartz
- Northeastern Society of Gynaecological Oncology, Germany; University, Greifswald, Germany; Charite, Berlin, Germany; University, Muenchen, Germany; Gertrauden, Berlin, Germany
| | - A. Belau
- Northeastern Society of Gynaecological Oncology, Germany; University, Greifswald, Germany; Charite, Berlin, Germany; University, Muenchen, Germany; Gertrauden, Berlin, Germany
| |
Collapse
|
25
|
Könsgen D, Belau A, Klare P, Camara O, Sommer H, Lichtenegger W, Sehouli J. Dose-finding study of Topotecan (T) plus Carboplatin (C) for patients with platinum sensitive Relapsed Ovarian Cancer (ROC). Geburtshilfe Frauenheilkd 2006. [DOI: 10.1055/s-2006-952826] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
26
|
Bartz K, Belau A, Nehmzow M, Köhler G. Chemotherapie bei der älteren Patientin–Modifikation effektiver Therapiekonzepte zwingend erforderlich? Geburtshilfe Frauenheilkd 2006. [DOI: 10.1055/s-2006-952509] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
27
|
Köhler G, Riebe E, Belau A. Vergebliche Liebesmüh – von der Venusdusche über die Glockenbrause zum Doppelkammerspüler – historische kontrazeptive Spülapparate. Geburtshilfe Frauenheilkd 2006. [DOI: 10.1055/s-2006-952561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
28
|
Burges A, Wollschläger K, Burchardi N, Belau A, Gropp M, Beckmann MW, Pfisterer J, duBois A. Die Kombinationschemotherapie aus PegLiposomalen Doxorubicin und Carboplatin bei bösartigen gynäkologischen Tumoren: Eine prospektive multizenter Phase II-Studie der AGO-OVAR. Geburtshilfe Frauenheilkd 2006. [DOI: 10.1055/s-2006-952197] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|
29
|
Koensgen D, Belau A, Klare P, Steck T, Camara O, Sommer H, Oskay-Oezcelik G, Coumbos A, Lichtenegger W, Sehouli J. Topotecan (T) and carboplatin (C) in the treatment of platinum sensitive relapsed ovarian cancer (ROC): Results of a multicenter phase I/II study. J Clin Oncol 2006. [DOI: 10.1200/jco.2006.24.18_suppl.5089] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
5089 Background: Despite of the effectiveness of radical surgery and first-line chemotherapy, most patients (pts) with advanced ovarian cancer will relapse. Paclitaxel (P) in combination with C as second-line treatment improves the outcome of pts with platinum-sensitive ROC in comparison to C monotherapy. Due to polyneuropathy and alopecia this regimen can not be offered to all pts. Therefore, other platinum-combinations are required. We conducted a phase I/II study to define the dose limiting toxicities (DLT) and the tolerability of combination therapy with T and C. Methods: Pts with platinum-sensitive ROC and primary standard therapy were stratified according to treatment-free interval (TFI): 6–12 months (A) and ≥12 months (B). Following dose regimens were analysed: T 1mg/m2/d1–3 + C AUC5/d3 and T 0.75 mg/m2/d1–3 + C AUC5/d3, q21d. DLT was based on the first 4 courses and defined as: CTC grade 3/4 hematological and grade 2 non-hematological toxicity (excepted alopecia, vomiting), treatment delay >7d. Primary endpoints were DLT and tolerability. Secondary endpoints were remission rate (RR) and progression-free survival (PFS). Results: From 06/04 to 08/05, 28 pts were enrolled, 26 pts (A:13 pts, B:13 pts) were eligible. Median age was 61.5 years. A total of 141 cycles were analysed, median number of cycles was 6 (range A:2–8, B:1–10). DLTs were: leucopenia (n = 5) and thrombocytopenia (n = 1). MTD was reached at dose: T: 0.75mg/m2 and C: AUC5. Overall, grade 3/4 hematologic toxicities (in% of all cycles), for (A) and (B) respectively, were: anemia 4% vs. 4%, leucopenia 34% vs. 13%, neutropenia 30% vs. 31%, thrombocytopenia 7% vs. 6%. Febrile neutropenia 4.3% vs. 0%. Darbepoetin alfa was given in 13.5% of all cycles. Overall, grade 3/4 non-hematologic toxicities were infrequent (< 5%). Overall RR (95% CI) was 50% (29.7–70.1) [A: 30.8% (0.1–61.1), B: 69.3% (38.7–90.9)]. Median follow-up was 5.8 mo, median PFS (95% CI) was 7.7 mo (1.3–9.4) [A: 6.2 (1.3–7.2), B: 8.0 (7.3–9.4)]. Median overall survival was not reached. Conclusions: TC is a feasible and effective chemotherapy regimen for platinum sensitive ROC. Tolerability is not associated to TFI. The recommended dose for subsequent studies is T:0.75 and C:AUC5. No significant financial relationships to disclose.
Collapse
Affiliation(s)
| | - A. Belau
- Medical University Charite, Berlin, Germany
| | - P. Klare
- Medical University Charite, Berlin, Germany
| | - T. Steck
- Medical University Charite, Berlin, Germany
| | - O. Camara
- Medical University Charite, Berlin, Germany
| | - H. Sommer
- Medical University Charite, Berlin, Germany
| | | | - A. Coumbos
- Medical University Charite, Berlin, Germany
| | | | - J. Sehouli
- Medical University Charite, Berlin, Germany
| |
Collapse
|
30
|
Hilpert F, Harter P, Reinartz S, Sehouli J, Loibl S, Canzler U, Belau A, Reuss A, Jackisch C, Pfisterer J. Phase I/II trial of the anti-idiotypic monoclonal antibody ACA125 in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer. J Clin Oncol 2005. [DOI: 10.1200/jco.2005.23.16_suppl.5018] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Affiliation(s)
- F. Hilpert
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| | - P. Harter
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| | - S. Reinartz
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| | - J. Sehouli
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| | - S. Loibl
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| | - U. Canzler
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| | - A. Belau
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| | - A. Reuss
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| | - C. Jackisch
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| | - J. Pfisterer
- AGO OVAR, Kiel, Germany; AGO OVAR, Wiesbaden, Germany; AGO OVAR, Marburg, Germany; AGO OVAR, Berlin, Germany; AGO OVAR, Frankfurt, Germany; AGO OVAR, Dresden, Germany; AGO OVAR, Greifswald, Germany
| |
Collapse
|
31
|
du Bois A, Belau A, Wagner U, Pfisterer J, Schmalfeldt B, Richter B, Staehle A, Jackisch C, Lueck HJ, Schroeder W, Burges A, Olbricht S, Elser G. A phase II study of paclitaxel, carboplatin, and gemcitabine in previously untreated patients with epithelial ovarian cancer FIGO stage IC-IV (AGO-OVAR protocol OVAR-8). Gynecol Oncol 2005; 96:444-51. [PMID: 15661234 DOI: 10.1016/j.ygyno.2004.10.020] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/08/2004] [Indexed: 10/26/2022]
Abstract
PURPOSE A multicenter, nonrandomized, phase II study was initiated to evaluate the tolerability, toxicity, and activity of paclitaxel, carboplatin, and gemcitabine combination in previously untreated ovarian cancer. PATIENTS AND METHODS Chemonaive patients who had radical debulking surgery for primary epithelial ovarian cancer International Federation of Gynecology and Obstetrics (FIGO) IC-IV received sequentially paclitaxel 175 mg/m(2), carboplatin AUC 5, and gemcitabine 800 mg/m(2) on day 1 and gemcitabine 800 mg/m(2) on day 8, every 3 weeks. RESULTS From October 2001 to July 2002, 55 patients were treated and evaluated. Main toxicities were hematological with NCI-CTC grade 3/4 anemia 12.7%, leukopenia 70.9%, neutropenia 76.3%, and thrombocytopenia 45.5. However, febrile neutropenia occurred only in 1.8%. Grade 3/4 nonhematological toxicities were rare and occurred in less than 10% of patients. Toxicity-induced treatment delays occurred in 3.1% of cycles and resulted in early treatment cessation in four patients. Dose intensity reached 90.8% for carboplatin and paclitaxel, and 73.3% for gemcitabine. Objective response was observed in 10 of 14 patients with measurable disease. CONCLUSIONS The triplet combination of paclitaxel-carboplatin-gemcitabine is feasible and active, with manageable hematological toxicity and no unexpected nonhematological toxicity. This regimen has proceeded to phase III evaluation.
Collapse
Affiliation(s)
- A du Bois
- Department of Gynecology and Gynecologic Oncology, and AGO Study Secretary, Dr. Horst Schmidt Klinik Wiesbaden (HSK), Ludwig-Erhard-Str. 100, D-65199 Wiesbaden, Germany.
| | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
32
|
Abstract
Magnetoencephalography (MEG) is a noninvasive option for localizing electroneurophysiological activity on the human cortex. The purpose of this study was to evaluate the practicability and reliability of MEG imaging integrated into a neuronavigation system to identify the sensorimotor cortex intraoperatively in patients with brain tumors in or near the central motor strip. It was performed prior to surgery in 30 patients with space-occupying lesions in or around the central region to localize the primary somatosensory cortex. These functional brain maps were superimposed on MR images obtained prior to surgery and transferred in the operating room for intraoperative functional neuronavigation. During surgery, the phase reversal technique identified a generator which coincided with the somatosensory cortex as displayed by the MEG-based functional neuronavigation system. Following surgery, the motor deficit improved in seven patients, was unchanged in five, and showed a slight transient deterioration in five. One patient suffered a deterioration of motor function with incomplete recovery. The MEG-based functional neuronavigation was found to be practicable and useful in finding a safe approach to tumors in or adjacent to the central region. The accuracy of MEG was concluded to be reliable as verified by the phase reversal technique.
Collapse
Affiliation(s)
- R Firsching
- Department of Neurosurgery, University of Magdeburg, Germany.
| | | | | | | | | | | | | |
Collapse
|
33
|
Belau A, Ohlinger R, Schwesinger G, Köhler G. Primäres Karzinosarkom der Mamma - klinische, mammographische, sonographische und histologische Befunde. Geburtshilfe Frauenheilkd 2002. [DOI: 10.1055/s-2002-25218] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022] Open
|